Perla A. Retana-Brown, PA-C

Perla Retana-Brown practices at CHRISTUS Health in Alamogordo, New Mexico, part of CHRISTUS Health.

Perla Retana-Brown's NPI, 1518439157, was assigned on December 20, 2018. Perla Retana-Brown holds Texas license PA12508.

Perla Retana-Brown's primary practice is CHRISTUS Health, at 2669 Scenic Drive, Alamogordo, NM 88310 in Otero County. The practice phone is (575) 439-6100.

Perla Retana-Brown's primary practice is CHRISTUS Health in Alamogordo, New Mexico, part of CHRISTUS Health. Perla Retana-Brown is also affiliated with Memorial Medical Center. The medical group on file is Integrated Rehab Consultants. Dmand AI also links Perla Retana-Brown to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Perla Retana-Brown practices, 3 sites in all. Vendor and product names are available with a free account.

Medical is Perla Retana-Brown's primary specialty in the NPI Registry, under taxonomy code 363AM0700X. Perla Retana-Brown is licensed in Texas.

Dmand AI lists chronic obstructive pulmonary disease (COPD), fibromyalgia and chronic pain, joint pain, osteoporosis, parkinson's disease, rheumatoid arthritis and tobacco use among the conditions Perla Retana-Brown treats.

CMS data shows 148 Medicare services from Perla Retana-Brown across 2 procedure codes in 2024, all of them office visits, for 160 Medicare patients. Medicare paid $11,333 for them. Every service was in an office.

CMS counts 160 Medicare patients who saw Perla Retana-Brown in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 3.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Perla Retana-Brown's median patient age at 55, with 80% women.

In 2024, Perla Retana-Brown wrote 260 Medicare Part D claims for 51 patients. 83% of them were for generic drugs. CMS names the drug for 23 of them, across 2 drugs with 11 or more claims each, at $102 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Perla Retana-Brown for performance year 2024, reported as part of a group. Perla Retana-Brown accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 122 general payments to Perla Retana-Brown from 17 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $594.